Published 09/25/2024 10:04:31 p.m.

Pfizer withdraws sickle cell disease treatment from all markets

Summary by CNBC

U.S. drugmaker Pfizer said on Wednesday it is withdrawing its sickle cell disease therapy Oxbryta in all markets where it is approved and discontinuing all studies and access programs related to the treatment.

0 Articles

All

Left

Center

Right

CNBC

Pfizer withdraws sickle cell disease treatment from all markets

09/25/2024 11:00:35 p.m.·United States

Read Full Article

MarketWatch

Pfizer yanks sickle-cell treatment worldwide after possible link to deaths

The benefits of Oxbryta no longer outweigh the risks, Pfizer says.

09/25/2024 9:36:00 p.m.·United States

Read Full Article

STAT

Pfizer pulls sickle cell treatment Oxbryta off global markets

Pfizer said Oxbryta's benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain crises and "fatal events."

09/25/2024 10:16:46 p.m.·Boston, United States

Read Full Article

BizToc

Pfizer withdraws sickle cell disease treatment from all markets

09/25/2024 10:04:31 p.m.

Read Full Article

Nairametrics

Pfizer withdraws $125,000 sickle cell treatment Oxbryta worldwide

Pfizer has announced the global withdrawal of its sickle cell disease treatment, Oxbryta (voxelotor), which was priced at approximately $125,000 per year. The post Pfizer withdraws $125,000 sickle cell treatment Oxbryta worldwide appeared first on Nairametrics.

09/26/2024 7:08:27 a.m.

Read Full Article

pipelinereview

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets - Pipelinereview

NEW YORK, NY, USA I September 25, 2024 I Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer’s decision is based on the totality of clinical data that now indicates the overall benef…

09/26/2024 6:35:46 a.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year